Immunovo BV Information

Immunovo BV is a Dutch private biotechnology company, based in 's-Hertogenbosch, engaged in the discovery and clinical development of immunotherapeutics in the field of oncology. The key priority for Immunovo is on its proprietary Immune Activation System (IAS*) based on combining synthetic peptide antigens with a novel immune stimulant (adjuvant). IAS* has the potential to be a truly disruptive technology in the immunotherapeutic field as crucially there are fewer economic factors in place which restrict access to wider numbers of patients in comparison to currently prescribed drugs. Immunovo was founded in 2009 by a group of experienced private investors together with Dr. Joost van Bree, a seasoned life science veteran and former CEO of Pepscan. Immunovo was spun out of Pepscan Holding NV, to be able to concentrate specifically on IAS*. The company currently has a Phase II prostate cancer project partnered with Novartis. A second project, targeting angiogenesis, is in phase I/II clinical testing at the VUmc (Free University Medical Center) in Amsterdam. Behind these programs lies a rich pipeline of IAS products targeting other key oncology targets. Immunovo's TLR-4 based immune stimulants outperform currently used adjuvants with respect to safety and efficacy. For the above technology, a full cGMP program has been completed and a robust manufacturing process is in place. From an ROI point of view, the cost of goods for the Immunovo adjuvants and antigens are comparatively several levels of magnitude lower than those commonly seen for antibodies.